<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR31">
 <label>31.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Longo</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Llorens</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Goetz</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Platini</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Eid</surname>
    <given-names>N</given-names>
   </name>
   <name>
    <surname>Sellies</surname>
    <given-names>J</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Taurolidine/citrate lock therapy for primary prevention of catheter-related infections in cancer patients: results of a prospective, randomized, phase IV trial (ATAPAC)</article-title>
  <source>Oncology</source>
  <year>2017</year>
  <volume>93</volume>
  <fpage>99</fpage>
  <lpage>105</lpage>
  <pub-id pub-id-type="doi">10.1159/000470911</pub-id>
  <?supplied-pmid 28463827?>
  <pub-id pub-id-type="pmid">28463827</pub-id>
 </element-citation>
</ref>
